Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT00268840 Completed - Clinical trials for Pancreatic Neoplasms

The Efficacy and Safety of Gemcitabine in Combination With Docetaxel to Treat Pancreatic or Biliary Cancer

Start date: August 2001
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy of combination therapy with gemcitabine and docetaxelin in patients with locally advanced or metastatic pancreatic or biliary adenocarcinoma.

NCT ID: NCT00266617 Completed - Neoplasms Clinical Trials

A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in Patients With Anemia as a Result of Advanced Cancer and Treatment With Aggressive Chemotherapy

Start date: n/a
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of epoetin alfa in the treatment of persistent anemia caused by advanced cancer and aggressive adriamycin-chemotherapy. Epoetin alfa is a genetically engineered protein that stimulates red blood cell production.

NCT ID: NCT00266279 Completed - Head or Neck Cancer Clinical Trials

Phase II (Treatment) Study of Oxaliplatin and Capecitabine in Advanced Head and Neck Malignancies

Start date: April 2005
Phase: Phase 2
Study type: Interventional

This phase II study will test the response rate of combined oxaliplatin and capecitabine treatment when administered at a given dose and schedule, in patients with Head and Neck cancer for which there is no curative treatment.

NCT ID: NCT00266084 Completed - Clinical trials for Uterine Cervical Cancer

Clinical Trial for the Use of a Novel Cell Collector Device to Retrieve Cells From the Uterine Cervix

Start date: August 1999
Phase: Phase 1/Phase 2
Study type: Observational

This study tested the safety and performance of a new cell collector device and compared the results to those obtained with the current existing device that are being used routinely

NCT ID: NCT00265057 Completed - Neoplasms Clinical Trials

Study of ADH-1 Given Intravenously to Patients With Solid Tumors

Start date: June 2005
Phase: Phase 1/Phase 2
Study type: Interventional

N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study will test the safety and effects of ADH-1 in subjects with incurable, solid tumors with a protein biomarker called N-cadherin. This study will identify the amount of ADH-1 that subjects can tolerate.

NCT ID: NCT00264446 Completed - Neoplasms Clinical Trials

A Study of ADH300004 in Surgically Resected Primary or Metastatic Colorectal Cancer and Liver Biopsy, or Planned Hepatic Resection

Start date: n/a
Phase: Phase 1
Study type: Interventional

5 fluorouracil (5 FU), one of the most actively investigated anti-cancer drugs, is rapidly inactivated by the enzyme dihydropyrimidine dehydrogenase (DPD). ADH300004 blocks DPD. This study will examine the kinetics of inhibition and recovery of the metabolic pathways for fluoropyrimidines in subjects who receive a single oral dose of ADH300004, and may allow optimization of oral 5 FU dosing to subjects in future studies.

NCT ID: NCT00264433 Completed - Neoplasms Clinical Trials

A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent

Start date: n/a
Phase: Phase 2
Study type: Interventional

N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study will test the safety and effects of ADH-1 in subjects with specific incurable, solid tumors with a protein biomarker called N-cadherin. This study will examine the clinical activity of ADH-1.

NCT ID: NCT00264108 Completed - Neoplasms Clinical Trials

Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia

Start date: June 2005
Phase: Phase 4
Study type: Observational

The purpose of this study is to evaluate the cost-effectiveness of epoetin alfa compared with darbepoetin alfa in the treatment of anemia in adults receiving chemotherapy for cancer. Epoetin alfa and darbepoetin alfa are genetically engineered proteins that stimulate red blood cell production.

NCT ID: NCT00264095 Completed - Neoplasms Clinical Trials

An Observational Study of Blood Management Techniques in Oncology Surgical Treatment

Start date: July 2004
Phase: Phase 4
Study type: Observational

The purpose of this study is to observe the methods used to manage blood loss in surgical procedures to remove tumors from patients with cancer and to determine if there is a relationship with the need for blood transfusions.

NCT ID: NCT00259129 Completed - Neoplasms Clinical Trials

Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients

Start date: August 2005
Phase: Phase 1
Study type: Interventional

This is an open-label, non-randomized Phase I study of sorafenib 400 mg bid (2 x 200 mg tablets) in cancer patients. The primary objective of the study is to evaluate the effect of sorafenib on cardiovascular safety parameters. The secondary objectives are to evaluate the safety, pharmacokinetics, and anti-tumor activity of sorafenib in cancer patients